Current status of adverse drugs reactions of cytokine release syndrome
10.13699/j.cnki.1001-6821.2018.07.049
- VernacularTitle:细胞因子释放综合征的不良反应研究现状
- Author:
Qi WANG
1
;
Tan ZHANG
;
Feng SU
;
Yi FANG
Author Information
1. 北京大学人民医院药剂科
- Keywords:
chimeric antigen receptor T cell therapy;
cytokine release syndrome;
interleukin 6 targeted antitumor agents
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(7):906-909
- CountryChina
- Language:Chinese
-
Abstract:
Cytokine release syndrome (CRS),a common adverse drug reaction in chimeric antigen receptor T cell therapy (CAR-T),is a newly immune anti-cancer regime,which modifies T cells extracted from patients into CAR-T cells through genetic engineering and then gives CAR-T back to patients for cancer control.CRS is widely concerned due to its high incidence and life-threatening risk.Studies have shown that elevated levels of interleukin 6 (IL-6) and other cytokines in vivo are the major causes of CRS,but very few IL-6 targeted drugs are currently available to control CRS.Therefore,in order to get a better control of CRS in CAR-T clinical treatment,this review will summarize some agents with IL-6 as the target and their applications reported in CRS management.
